Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

OAOdelia AmitGFGil FridbergYMYakir Moshe

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows sequential therapy enhances remission in older AML patients, indicating effective GVHD management.

Key Points

  • To evaluate the effectiveness of FITCy regimen in elderly patients with active AML undergoing allogeneic transplantation.
  • Single center retrospective analysis of AML patients aged over 70
  • Utilized a modified reduced-intensity conditioning regimen
  • Assessed outcomes including GVHD and overall survival
  • 90% of evaluable patients achieved complete remission by day 30
  • Cumulative one-year overall survival was 53%
  • Significant association found between venetoclax therapy and improved outcomes

Cite This Study

Amit et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba1https://doi.org/10.1182/blood-2025-5973
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential therapy with allogeneic HCT in patients aged ≥70 years with active AML: a singlecenter retrospective analysis2026
  2. 2Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial2025
  3. 3Older age as a predictor of post-transplant survival in newly diagnosed acute myeloid leukemia treated with HMA-venetoclax.2026
  4. 4Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia2026 · 1 citations
  5. 5Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)2025